Biogen (NasdaqGS:BIIB) received Breakthrough Therapy Designation from the FDA for litifilimab in cutaneous lupus erythematosus. The company reported phase 2/3 trial results for high dose nusinersen in ...
Findings from DEVOTE support clinical benefits of the high-dose regimen of nusinersen (50 mg and 28 mg) in both ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window BOSTON -- Upper ...
Across the studies of a new analysis, there was a significant risk difference in motor milestone response and improvement in Hammersmith Infant Neurological Examination score. Although more ...
Researchers of the multicenter study looked at the effect of nusinersen among 48 patients with spinal muscular atrophy (SMA) from 2 Italian hospitals, finding more active immune systems among the ...
BOSTON -- Older children with spinal muscular atrophy (SMA) Types 2 and 3 achieved greater improvements in motor function with nusinersen (Spinraza) compared with a sham injection, but the benefits of ...
Please provide your email address to receive an email when new articles are posted on . Treatment with nusinersen led to continued and improved motor function up to 5 years after initial dose in ...
Children with later-onset spinal muscular atrophy benefited from three years of treatment with the anti-sense oligonucleotide nusinersen, according to a paper in today’s Neurology. Motor function ...
Nusinersen injection is injected intrathecally (into the backbone) over 1-3 minutes so that it reaches the cerebrospinal fluid (CSF), the fluid that bathes the brain and the spinal cord. Dosage & When ...
Treatment with SPINRAZA improved or stabilized motor function across patient populations, including young adults The longer-term safety profile of SPINRAZA was consistent among a broad spectrum of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results